CA2419572A1 - Preparation a forte concentration de protease - Google Patents

Preparation a forte concentration de protease Download PDF

Info

Publication number
CA2419572A1
CA2419572A1 CA002419572A CA2419572A CA2419572A1 CA 2419572 A1 CA2419572 A1 CA 2419572A1 CA 002419572 A CA002419572 A CA 002419572A CA 2419572 A CA2419572 A CA 2419572A CA 2419572 A1 CA2419572 A1 CA 2419572A1
Authority
CA
Canada
Prior art keywords
protease
uusp
pharmaceutical composition
pancreatin
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002419572A
Other languages
English (en)
Inventor
Unknown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptalis Pharma Canada ULC
Original Assignee
Axcan Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcan Pharma Inc filed Critical Axcan Pharma Inc
Priority to CA002419572A priority Critical patent/CA2419572A1/fr
Priority to PCT/CA2004/000228 priority patent/WO2004074470A1/fr
Publication of CA2419572A1 publication Critical patent/CA2419572A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/94—Pancreatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002419572A 2003-02-18 2003-02-18 Preparation a forte concentration de protease Abandoned CA2419572A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002419572A CA2419572A1 (fr) 2003-02-18 2003-02-18 Preparation a forte concentration de protease
PCT/CA2004/000228 WO2004074470A1 (fr) 2003-02-18 2004-02-18 Pancreatine a haute teneur en protease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002419572A CA2419572A1 (fr) 2003-02-18 2003-02-18 Preparation a forte concentration de protease

Publications (1)

Publication Number Publication Date
CA2419572A1 true CA2419572A1 (fr) 2004-08-18

Family

ID=32855086

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002419572A Abandoned CA2419572A1 (fr) 2003-02-18 2003-02-18 Preparation a forte concentration de protease

Country Status (2)

Country Link
CA (1) CA2419572A1 (fr)
WO (1) WO2004074470A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015019198A3 (fr) * 2013-07-22 2015-05-28 Aptalis Pharma Ltd. Compositions pharmaceutiques de pancréatine de puissance élevée
US9259393B2 (en) 2000-11-15 2016-02-16 Aptalis Pharma S.R.L. Microspheres of pancreatic enzymes with high stability and production method thereof
US9976171B2 (en) 2011-08-08 2018-05-22 Allergan Pharmaceuticals International Limited Method for dissolution testing of solid compositions containing digestive enzymes
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
US10206882B2 (en) 2007-02-20 2019-02-19 Allergan Pharmaceuticals International Limited Stable digestive enzyme compositions
US10993996B2 (en) 2013-08-09 2021-05-04 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
US11364205B2 (en) 2010-10-01 2022-06-21 Societe Des Produits Nestle S.A. Stable low digestive enzyme content formulation

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613429A1 (fr) * 2013-11-05 2020-02-26 Allergan Pharmaceuticals International Limited Compositions pharmaceutiques de pancréatine de haute puissance
CN112080487B (zh) * 2019-06-14 2024-03-26 苏州融析生物科技有限公司 一种羊胰酶制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3248588A1 (de) * 1982-12-30 1984-07-12 Nordmark-Werke Gmbh, 2000 Hamburg Verfahren zur gewinnung von pankreatin von hohem schuettgewicht
DE3377506D1 (en) * 1982-12-30 1988-09-01 Nordmark Arzneimittel Gmbh Process for obtaining pancreatin
DE4203315A1 (de) * 1991-02-14 1992-08-20 Kali Chemie Pharma Gmbh Verfahren zur gewinnung von pankreatin
US5861291A (en) * 1997-02-24 1999-01-19 Biozymes Inc. Method for producing pancreatin which contains low amounts of residual organic solvent and product thereof

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9259393B2 (en) 2000-11-15 2016-02-16 Aptalis Pharma S.R.L. Microspheres of pancreatic enzymes with high stability and production method thereof
US9884025B2 (en) 2000-11-15 2018-02-06 Aptalis Pharma S.R.L. Microspheres of pancreatic enzymes with high stability and production method thereof
US10206882B2 (en) 2007-02-20 2019-02-19 Allergan Pharmaceuticals International Limited Stable digestive enzyme compositions
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US11364205B2 (en) 2010-10-01 2022-06-21 Societe Des Produits Nestle S.A. Stable low digestive enzyme content formulation
US9976171B2 (en) 2011-08-08 2018-05-22 Allergan Pharmaceuticals International Limited Method for dissolution testing of solid compositions containing digestive enzymes
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
WO2015019198A3 (fr) * 2013-07-22 2015-05-28 Aptalis Pharma Ltd. Compositions pharmaceutiques de pancréatine de puissance élevée
CN105392496A (zh) * 2013-07-22 2016-03-09 阿普塔利斯制药有限公司 高效的胰酶药物组合物
RU2686460C2 (ru) * 2013-07-22 2019-04-26 Апталис Фарма Лтд. Высокоэффективные фармацевтические композиции панкреатина
US10993996B2 (en) 2013-08-09 2021-05-04 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration

Also Published As

Publication number Publication date
WO2004074470A1 (fr) 2004-09-02

Similar Documents

Publication Publication Date Title
KR101333664B1 (ko) 췌장 기능부전을 치료하기 위한 리파제, 프로테아제 및아밀라제 함유 조성물
US7122357B2 (en) Method for the treatment of diabetes
Ferrone et al. Pancreatic enzyme pharmacotherapy
US4485095A (en) Pronase used for the treatment of diseases of the liver and kidneys in humans and animals
US20100196344A1 (en) Compositions and methods for treating pancreatic insufficiency
Jiang et al. The impact of micronized purified flavonoid fraction on the treatment of acute haemorrhoidal episodes
CA2419572A1 (fr) Preparation a forte concentration de protease
US20180104317A1 (en) Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance
Kulthanan et al. Angioedema: clinical and etiological aspects
JP5199919B2 (ja) ヒトデコラーゲンペプチドを有効成分とする血糖値上昇抑制剤およびヒトデコラーゲンペプチドの製造方法
Keller et al. Pancreatic enzyme supplementation therapy
Pedersen et al. LongoVital in the treatment of Sjögren’s syndrome
US6013680A (en) Digestive enzyme-containing medicament
US20130039999A1 (en) Use of clays for treating coeliac disease
Ruseler-van Embden et al. Increased proteolysis and leucine aminopeptidase activity in faeces of patients with Crohn’s disease
Huang et al. AB0379 IS MYCOPHENOLATE SODIUM (MYFORTIC) SIMILARLY EFFECTIVE AS MYCOPHENOLATE MOFETIL (CELLCEPT) IN TREATMENT OF LUPUS NEPHRITIS? EXPERIENCE FROM NON-MEDICAL SWITCHING REAL WORLD DATA IN TAIWAN
Huang et al. AB0380 THERAPEUTIC CHOICES AND OUTCOMES IN CHINESE PATIENTS WITH SEROLOGICALLY ACTIVE CLINICALLY QUIESCENT SYSTEMIC LUPUS ERYTHEMATOSUS
RU2171688C2 (ru) Способ лечения реактивного панкреатита у детей
Sato et al. Case of an elderly man with associated Henoch-Schönlein purpura during treatment of acute pancreatitis
Sulikowska et al. IgA Nephropathy–selected problems including older patients Nefropatia IgA–wybrane zagadnienia z uwzględnieniem chorych w wieku starszym
Saito et al. Lysosomal enzyme activities in rat kidney treated with DOCA, especially with reference to renin, cathepsin and β-glucuronidase
Cornell et al. Enzyme therapy for coeliac disease: Is it ready for prime time?
CN114761015A (zh) 中性粒细胞弹性蛋白酶抑制剂在肺病中的用途
Jacobsson et al. Dry eyes and/or mouth and keratoconjunctivitis sicca in an adult Swedish population
JPH11189544A (ja) 消化酵素含有医薬品

Legal Events

Date Code Title Description
FZDE Dead